Today's Date: May 9, 2021
IPG Mediabrands Shares Media Equity Commitment to Encourage Investment in Black-Owned Media   •   Publix Accepts Walk-in Customers for COVID‑19 Vaccinations in All Seven of Its States   •   MedShare to Give Expectant Mothers in Underserved Bay Area Communities Access to State-of-the-Art Philips Ultrasound Imaging Sol   •   Skypod Supports American Pregnancy Association   •   AHF Issues $100M Homeless Challenge to Mayor Garcetti, L.A. City Council in New L.A. Times Ad   •   Sen. Jon Ossoff Announces that Clark Atlanta University Will Receive Approximately $16.4 Million from the American Rescue Plan   •   Short documentary Dear Georgina spotlighting life of Passamaquoddy elder streaming launch May 7   •   Mother's Day: Xi Inspired by His Mother in Shaping Outlook on Life, Governance   •   Waldencast Acquisition Corp. Announces the Separate Trading of Its Class A Ordinary Shares and Redeemable Warrants Commencing Ma   •   United Way of King County Launches New Campaign to Address Growing Food Insecurity Due to Pandemic   •   UBS Declares Coupon Payments on 5 ETRACS Exchange Traded Notes   •   Women in Manufacturing Association Announces “Moms in MFG,” a New Event for Moms Working in the Manufacturing Sector   •   HCSS Hosts TWU Houston 2021 Graduation With Drive-Through Event   •   Minister Miller talks about mental wellness during the pandemic   •   Six Flags Hurricane Harbor to Reopen May 15   •   Supporting Local Communities: PG&E Contributes $200,000 to Celebrate and Support the Asian American Pacific Islander Communi   •   Graymoor Ecumenical and Interreligious Institute Shares Theme for 2022 Week of Prayer for Christian Unity   •   The Tech Convenes Top STEM Professionals to Advise Young Women on Career Paths   •   Hello Sunshine’s Fair Play Brand, Glamour and CVS To Host “Dare to Self-Care” Virtual Wellness Event on May 10   •   CGTN: How does Xi Jinping express gratitude and love to his mother?
Bookmark and Share

Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress

SOUTH SAN FRANCISCO, Calif. , May 04 /Businesswire/ - Veracyte, Inc. (Nasdaq: VCYT) announced today that new data relating to the Prosigna® Breast Cancer Gene Signature Assay will be presented at the European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 taking place May 5-8.

“New data accepted for presentation at this year’s ESMO Breast Cancer Congress provide further evidence for the importance of genomic testing in breast cancer, particularly to help physicians and patients make better informed treatment decisions based on the unique biology of individual patients’ tumors,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “We believe such data strengthen the backdrop for our Prosigna Breast Cancer Gene Signature Assay, and greatly appreciate the breast cancer experts who led and participated in these studies.”

Following are details of the Prosigna-related posters accepted for presentation at the ESMO Breast Cancer Virtual Congress. These abstracts are available to meeting registrants on demand:

Title:

 

Influence of PAM50 on therapeutic decisions in patients with early-stage Luminal Breast Cancer in a single centre

Poster:

 

62P

First Author:

 

Alejandro Olivares-Hernandez, M.D., M.Sc., IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain

 

 

 

Title:

 

Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European Breast Cancer clinicians - The PROCURE project

Poster:

 

24P

First Author:

 

Giuseppe Curigliano, M.D., Ph.D., IEO - Istituto Europeo di Oncologia, Milan, Italy

The first poster will present findings from a prospective study conducted at the University Hospital of Salamanca (Spain), evaluating the influence of the PAM50 gene signature, the foundation of the Prosigna assay, on therapeutic decision-making for 143 patients with early-stage breast cancer.

The second poster will feature initial findings and consensus from the first wave of the PROCURE (Prosigna Clinical Utility Review) project, a European study utilizing the Delphi methodology to generate consensus regarding the clinical utility of genomic tests, including the Prosigna Breast Cancer Gene Signature Assay, in breast cancer treatment. The study is led by an independent scientific committee of eight breast cancer experts with input from 141 breast cancer clinicians practicing in nearly a dozen European countries.

About Prosigna

The Prosigna Breast Cancer Gene Signature Assay is a prognostic genomic test, built from PAM50 molecular subtypes, which combines tumor gene expression with clinicopathologic factors to better inform treatment decisions. The assay is indicated in female breast cancer patients who have undergone either mastectomy or breast-conserving therapy in conjunction with locoregional treatment consistent with standard of care, either as a prognostic indicator for distant recurrence-free survival at 10 years in post-menopausal women with Hormone Receptor-Positive (HR+), lymph node-negative, Stage I or II breast cancer, or lymph node-positive (1–3 positive nodes, or 4 or more positive nodes), Stage II or IIIA breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors. Outside of the United States, the Prosigna Breast Cancer Gene Signature Assay also provides the intrinsic subtypes of the tumor tissue within three groups, low, intermediate and high, by the nCounter Analysis System through decentralized performance.

The Prosigna test is FDA 510(k) cleared in the United States for use on the nCounter Analysis System and is available for use when ordered by a physician. The Prosigna test has received CE Mark and is available for use by healthcare professionals in the European Union and other countries that recognize the CE Mark, as well as in Canada, Israel, Australia, New Zealand and Hong Kong. The assay is covered by Medicare and leading private payers in the United States, and is widely covered by government and private payers in the countries where it is available.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the Prosigna Breast Cancer Gene Signature Assay. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," “suggest,” "may," "will" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracyte’s belief that the PAM50 gene signature and the Prosigna assay provide clinical value that help clinicians make therapeutic decisions. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: Veracyte’s ability to achieve and maintain Medicare coverage for its tests; the benefits of Veracyte’s tests and the applicability of clinical results to actual outcomes. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 22, 2021 and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts Veracyte’s businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, Afirma, Percepta, Envisia, Prosigna, "Know by Design" and the Veracyte, Afirma, Percepta, Envisia and Prosigna logos are registered trademarks of Veracyte in the U.S. and selected countries.

nCounter is the registered trademark of NanoString Technologies, Inc. in the United States and other countries and used by Veracyte under license.


STORY TAGS: Research, Medical Supplies, Women, Genetics, Biotechnology, General Health, Consumer, Health, Science, Oncology, United States, North America, California, Webcast, Trade Show, Conference,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News